Please sign in to follow a disease.
Eggs on the menu: could a daily dozen slow vision loss?
NCT ID NCT07021027
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether older adults with intermediate age-related macular degeneration (AMD) can eat 2 or 4 whole eggs daily for 5 months. The main goal is to see if people can stick with the diet, not to prove eggs improve vision. Researchers will also measure changes in eye function, thinking, and physical ability to plan a larger future trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- whole eggs (Eggland's Best)
- What this could lead to
- If successful, this could pave the way for a larger trial exploring whether eating eggs might help slow vision loss in people with intermediate AMD.
- What could go wrong
- This is a very small, early feasibility study with only 19 participants and no placebo group. It is not designed to prove that eggs improve eye health, only that people can stick to the diet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
19 people
The number who actually took part.
- Started
-
Jun 2025
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed with intermediate dry AMD as noted in their medical record (defined as having multiple medium drusen, at least one large druse (\>125 μm or the approximate size of a vessel coming off the optic nerve), and/or non-center involving geographic atrophy) who are BCVA stable from prior exam within 6 months - defined by change of \< 10 letters on EDTRS chart (BCVA within 10 letters within past 6 months) * 55 years of age and older * Willing to limit consumption of eggs for one month prior to beginning the study intervention * Willing to follow diet protocol * Body Mass Index (22.0 - 39.9 kg/m2) * Access to refrigeration * Access to reliable transportation Exclusion Criteria: * Presence of retinal pathology such as central geographic atrophy, hemorrhage or retinal fluid and other macular pathology other than AMD * Presence of dense cataracts * Presence of glaucoma * Previous retinal laser or surgical therapy that has impacted the integrity of the retina * Any other ocular condition requiring long-term therapy or surgery during the study period * Participant has photographically significant corneal or media opacities in either eye that would preclude adequate ophthalmic imaging and functional testing * Diagnosis of nystagmus that will interfere with testing * Egg allergy * Uncontrolled hyperlipidemia (cholesterol \>240 mg/dL in the last 12 months, unless under active medication management to achieve \<240 mg/dL)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Intermediate age-related macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Center for Living
Durham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.